Edition:
United Kingdom

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.42USD
25 Sep 2018
Change (% chg)

$-0.01 (-2.26%)
Prev Close
$0.43
Open
$0.42
Day's High
$0.43
Day's Low
$0.41
Volume
21,984
Avg. Vol
127,662
52-wk High
$8.70
52-wk Low
$0.31

Latest Key Developments (Source: Significant Developments)

Cytori Therapeutics Files Prospectus Relates To Offer, Sale Of Co's Stock
Friday, 21 Sep 2018 

Sept 21 (Reuters) - Cytori Therapeutics Inc ::CYTORI THERAPEUTICS FILES PROSPECTUS RELATES TO OFFER, SALE OF UP TO 3.7 MILLION SHARES OF CO'S COMMON STOCK BY LINCOLN PARK CAPITAL FUND LLC - SEC FILING.  Full Article

Cytori Therapeutics Enters Agreement With B. Riley FBR To Sell Its Shares
Friday, 1 Jun 2018 

June 1 (Reuters) - Cytori Therapeutics Inc ::CYTORI THERAPEUTICS INC - ON JUNE 1, ENTERED SALES AGREEMENT WITH B. RILEY FBR TO SELL ITS SHARES WITH AGGREGATE OFFERING PRICE OF UP TO $6.5 MILLION.  Full Article

Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cytori Therapeutics Inc ::SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING‍​.  Full Article

Cytori Therapeutics Inc ‍announces new investigator initiated U.S. clinical trial for hip osteonecrosis​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Cytori Therapeutics Inc :Cytori Therapeutics Inc - ‍announced a new investigator initiated U.S. clinical trial for hip osteonecrosis​.  Full Article

Cytori reports Q3 loss per share $0.14
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cytori Therapeutics Inc :Cytori reports third quarter 2017 business and financial results.Q3 loss per share $0.14.Cytori Therapeutics Inc - ‍received U.S. FDA IDE approval for relief, a thermal burn pilot trial related to ongoing barda contract​.Cytori Therapeutics Inc - ‍expects full year 2017 operating cash burn to be lower than 2016, primarily due to restructuring announced in September 2017​.  Full Article

BRIEF-Cytori Says Received Notice From Roche Diagnostics Terminating Supply Agreement With Co

* CYTORI THERAPEUTICS INC SAYS RECEIVED WRITTEN NOTICE FROM ROCHE DIAGNOSTICS CORPORATION TERMINATING EXISTING SUPPLY AGREEMENT WITH CO - SEC FILING